Phaseline

Companies › Palatin Technologies

Palatin Technologies: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine, Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PL8177
Melanocortin receptor agonist
MCIRPhase 2Ulcerative Colitis–
bremelanotide
Melanocortin receptor 4 agonist
MC4RPhase 2Obesity–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06565611bremelanotidePhase 2ObesityMetabolic and endocrineFeb 2025
NCT05466890PL8177Phase 2Ulcerative ColitisImmunologyFeb 2025

From the company's SEC filings

Cash of $7m on 2026-06-30; operating cash outflow about $14m a year; runway about 7 months at that burn, to Jan 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MC4R (1) MCIR (1)

Companies with the same targets

Rhythm Pharmaceuticals

Companies built like this

Oneness Biotech Rhythm Pharmaceuticals Biomea Fusion Enlivex Therapeutics Yarrow Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.